المؤلفون: Maria Cristina Campopiano, R. Michael Tuttle, Paolo Piaggi, Fulvio Basolo, Laura Agate, Luciana Puleo, David Viola, Rossella Elisei, Laura Valerio, Letizia Pieruzzi, Paolo Vitti, Loredana Lorusso, Antonio Matrone, Valeria Bottici, Carlotta Giani, Virginia Cappagli, Liborio Torregrossa, Eleonora Molinaro

المصدر: J Clin Endocrinol Metab

مصطلحات موضوعية: Male, observation, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Thyroid Gland, Biochemistry, microcarcinoma, Endocrinology, Risk Factors, Thyroid cancer, Ultrasonography, Incidence, Incidence (epidemiology), Thyroid, Middle Aged, Online Only, Treatment Outcome, medicine.anatomical_structure, Italy, Practice Guidelines as Topic, outcome, Disease Progression, Thyroidectomy, Female, Radiology, management, Adult, medicine.medical_specialty, differentiated thyroid cancer, Context (language use), Internal medicine, differentiated thyroid cancer, microcarcinoma, active surveillance, management, observation, outcome, medicine, Humans, Thyroid Neoplasms, Watchful Waiting, business.industry, active surveillance, Biochemistry (medical), Disease progression, medicine.disease, Carcinoma, Papillary, Neck ultrasound, Feasibility Studies, Observational study, Lymph Nodes, business, Clinical progression, Follow-Up Studies

الوصف: Context The dramatic rise in the incidence of thyroid cancer over the last 30 years is largely attributable to the increasing diagnosis of papillary microcarcinomas (mPTCs). Current guidelines endorse an observational management approach in properly selected cases. Objective To evaluate the feasibility of active surveillance in mPTC in Italy, its impact on real life, and to identify risk factors of progression. Design and setting In 2014 we started a prospective–observational study of active surveillance in mPTC patients. Patients Included patients demonstrated a single Thy4 or Thy5 thyroid nodule, with largest diameter ≤1.3 cm, and no suspicious laterocervical lymph nodes by neck ultrasonography. Of 185 eligible subjects, 50.3% (93/185) enrolled in the observational management protocol while the others opted for surgery and were excluded from this analysis. Intervention Enrolled patients were followed with neck ultrasound at 6- to 12-month intervals. Disease progression was defined as the appearance of abnormal lymph nodes or nodule enlargement during follow-up. In these cases, patients were directed to surgery. Results Three patients (3/93, 3%) showed clinical progression and required surgery. Another 19 patients (19/93, 20%) decided to transition to surgical intervention even though there was no evidence of disease progression. All operated patients had excellent response to initial treatment despite the delayed surgery. Conclusions Within an Italian medical context, active surveillance appears to be a feasible and safe alternative to immediate surgery in healthy mPTC patients. Only 3% of mPTC demonstrated disease progression during a median follow-up of 19 months (range 6–54) and importantly demonstrated excellent outcomes after surgical intervention in a short-term follow-up.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a21276832fdc4f71f518747b0370fc8Test
https://doi.org/10.1210/clinem/dgz113Test

المؤلفون: Liborio Torregrossa, Cristina Romei, Antonio Matrone, Clara Ugolini, Gabriele Materazzi, Laura Agate, Teresa Ramone, Paolo Piaggi, Carlotta Giani, Rossella Elisei, Eleonora Molinaro, Raffaele Ciampi, Fulvio Basolo

مصطلحات موضوعية: Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, whole tumor capsule, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Thyroid Gland, 030209 endocrinology & metabolism, Context (language use), Carcinoma, Papillary, Follicular, medicine.disease_cause, Biochemistry, Gastroenterology, Papillary thyroid cancer, Thyroid carcinoma, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Follicular phase, Adenocarcinoma, Follicular, medicine, Humans, papillary thyroid cancer, Thyroid Neoplasms, Good outcome, Thyroid cancer, Pathological, Thyroid neoplasm, follicular variant, business.industry, Biochemistry (medical), Middle Aged, medicine.disease, Prognosis, classical variant, Thyroid Cancer, Papillary, 030220 oncology & carcinogenesis, Mutation, Female, business

الوصف: Context Tumor capsule integrity is becoming a relevant issue to predict the biological behavior of human tumors, including thyroid cancer. Objective This work aims to verify whether a whole tumor capsule in the classical variant of papillary thyroid carcinoma (CVPTC) could have as a predictive role of a good outcome as for follicular variant (FVPTC). Methods FVPTC (n = 600) and CVPTC (n = 554) cases were analyzed. We distinguished between encapsulated-FVPTC (E-FVPTC) and encapsulated-CVPTC (E-CVPTC) and, thereafter, invasive (Ei-FVPTC and Ei-CVPTC) and noninvasive (En-FVPTC and En-CVPTC) tumors, according to the invasion or integrity of the tumor capsule, respectively. Cases without a tumor capsule were indicated as invasive-FVPTC (I-FVPTC) and invasive-CVPTC (I-CVPTC). The subgroup of each variant was evaluated for BRAF mutations. Results E-FVPTC was more frequent than E-CVPTC (P Conclusion En-CVPTC is less prevalent than En-FVPTC. However, it has good clinical/ pathological behavior comparable to En-FVPTC. This finding confirms the good prognostic role of a whole tumor capsule in CVPTC as well. New nomenclature for En-CVPTC, similar to that introduced for En-FVPTC (ie, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; NIFTP) could be envisaged.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c3dbf78e9ae408a111ff3406b3f2292Test
http://hdl.handle.net/11568/1103062Test

المؤلفون: Giovanni Pellegrini, Laura Agate, Chiara Fustini, Eleonora Molinaro, Paolo Piaggi, Rossella Elisei, David Viola, Valeria Bottici, Cristina Romei, Loredana Lorusso

المساهمون: University of Zurich, Elisei, Rossella

المصدر: Thyroid : official journal of the American Thyroid Association. 31(7)

مصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, Prognostic factor, endocrine system diseases, Adolescent, Endocrinology, Diabetes and Metabolism, Thyroid Gland, 10184 Institute of Veterinary Pathology, Young Adult, Text mining, Endocrinology, Internal medicine, medicine, Biomarkers, Tumor, Doubling time, Brain Stem Neoplasms, Humans, In patient, Antigens, Tumor-Associated, Carbohydrate, Thyroid Neoplasms, Aged, business.industry, Medullary thyroid cancer, Middle Aged, medicine.disease, Prognosis, 1310 Endocrinology, Diabetes and Metabolism, Survival Rate, 2712 Endocrinology, Diabetes and Metabolism, Response Evaluation Criteria in Solid Tumors, Calcitonin, Disease Progression, 570 Life sciences, biology, CA19-9, Female, business

الوصف: Background: Serum Ca19.9 positivity is a prognostic factor for mortality in patients with advanced medullary thyroid cancer (aMTC), independently from calcitonin doubling time (DT). However, it is ...

وصف الملف: thy.2020.0060.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fee3d3d64af302185bb8703303e38f2bTest
https://pubmed.ncbi.nlm.nih.gov/33234054Test

المؤلفون: Antonio, Matrone, Francesco, Latrofa, Liborio, Torregrossa, Paolo, Piaggi, Carla, Gambale, Alessio, Faranda, Debora, Ricci, Laura, Agate, Eleonora, Molinaro, Fulvio, Basolo, Paolo, Vitti, Rossella, Elisei

مصطلحات موضوعية: Adult, Male, Lymphocytic thyroiditis, Radioiodine ablation, Thyroid Gland, Thyroglobulin antibodies, Middle Aged, Thyroid Function Tests, Differentiated thyroid cancer, Thyroglobulin, Carcinoma, Papillary, Diabetes and Metabolism, Young Adult, Treatment Outcome, Endocrinology, Diabetes and Metabolism, Endocrinology, Thyroidectomy, Humans, Female, Thyroid Neoplasms, Aged, Autoantibodies

الوصف: Thyroglobulin (Tg) antibodies (TgAb) can interfere with Tg measurement and can be used as "Tg surrogate" in patients with differentiated thyroid cancer (DTC) treated with total thyroidectomy (TTx) and radioiodine remnant ablation (RRA). In contrast, few data, and in patients usually followed for a short-term follow-up, have been reported about the changes of TgAb levels in patients treated with TTx but without RRA. The aims of this study were to evaluate the changes of TgAb levels in DTC patients treated with TTx but not RRA and to identify the factors that influence these changes.The change in TgAb levels in 107 DTC (1 cm) patients submitted to TTx but not RRA was evaluated. Patients were followed for a median of 6.3 years, and all had at least three determinations of TgAb and neck ultrasound (nUS).TgAb levels showed a progressive decrease during follow-up. Initial TgAb levels and degree of lymphocytic infiltration influenced the time but not the rate of TgAb disappearance. No influence on time and rate of the decrease in TgAb was observed when the association with thyroperoxidase antibodies (TPOAb) levels were considered. A TgAb cutoff value of 61.9 IU/mL at first postoperative evaluation was a good indicator for disappearance of the TgAb within six years. No tumor recurrence was observed in the series. In one case, the progressive increase in TgAb anticipated the reappearance of benign thyroid tissue with lymphocytic infiltration.TgAb levels decline in the majority of DTC patients treated with TTx but not ablated with radioiodine. The levels decrease rapidly after the surgical treatment and continue to decrease over time. The time of disappearance is influenced by the initial TgAb levels and the degree of lymphocytic infiltration. No influence of the actual TPOAb levels has been observed. An increase in TgAb levels should not be overlooked, since it can indicate the presence or reappearance of either normal thyroid tissue or tumor recurrence.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7285fd6daa2bb80e47a2a119f53ce32dTest
http://hdl.handle.net/11568/939715Test

المؤلفون: Cristiana Lupi, Riccardo Giannini, Cristina Romei, David Viola, Liborio Torregrossa, Paolo Miccoli, Agnese Biagini, Fulvio Basolo, Paolo Piaggi, Paolo Vitti, Eleonora Molinaro, Aldo Pinchera, Laura Valerio, Rossella Elisei, Clara Ugolini, Gabriele Materazzi, Laura Agate

المصدر: The Journal of Clinical Endocrinology & Metabolism. 97:4390-4398

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Prognostic factor, medicine.medical_specialty, Adolescent, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Mutation, Missense, Thyroid Gland, Glutamic Acid, Biochemistry, Cohort Studies, Thyroid carcinoma, Young Adult, Endocrinology, Risk Factors, Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Thyroid Neoplasms, Single institution, Aged, Aged, 80 and over, business.industry, Genomic sequencing, Carcinoma, Biochemistry (medical), Genetic Alteration, Valine, Middle Aged, Prognosis, Carcinoma, Papillary, Large cohort, BRAF V600E, Amino Acid Substitution, Thyroid Cancer, Papillary, Sample Size, Female, Polymorphism analysis, business

الوصف: The BRAF(V600E) mutation, the most frequent genetic alteration in papillary thyroid carcinoma (PTC), was demonstrated to be a poor prognostic factor. The aim of this study was to evaluate its prognostic significance in a large cohort of low-risk intrathyroid PTC.Among the 431 consecutive PTC patients, we selected 319 patients with an intrathyroid tumor and no metastases (T1-T2, N0, M0). The BRAF(V600E) mutation was analyzed by PCR-single-strand conformation polymorphism analysis and direct genomic sequencing. The correlation between the presence/absence of the mutation, the clinical-pathological features, and the outcome of the PTC patients was investigated.The BRAF(V600E) mutation was present in 106 of 319 PTC patients (33.2%). Its prevalence was also the same in subgroups identified according to the level of risk. The BRAF(V600E) mutation correlated with multifocality, aggressive variant, absence, or infiltration of the tumoral capsule. BRAF(V600E)-mutated PTC also required a higher number of radioiodine courses to obtain disease-free status. The BRAF(V600E) mutation was the only prognostic factor predicting the persistence of the disease in these patients after 5 yr of follow-up.The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor for the persistence of the disease independent from other clinical-pathological features in low-risk intrathyroid PTC patients. It could be useful to search for the BRAF(V600E) mutation in the workup of low-risk PTC patients to distinguish those who require less or more aggressive treatments. In particular, the high negative predictive value of the BRAF(V600E) mutation could be useful to identify, among low-risk PTC patients, those who could avoid 131-I treatment.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8966db90c3ae64199b96ec9dbc04f591Test
https://doi.org/10.1210/jc.2012-1775Test

المؤلفون: Aldo Pinchera, Alessandra Capodanno, Paola Collecchi, Laura Agate, Fy Miasaki, Agnese Vivaldi, Raffaele Ciampi, Rossella Elisei

المصدر: Scopus-Elsevier

مصطلحات موضوعية: Antimetabolites, Antineoplastic, Receptors, Retinoic Acid, Endocrinology, Diabetes and Metabolism, Cell, Thyroid Gland, Retinoic acid, Biology, Decitabine, Transfection, chemistry.chemical_compound, Endocrinology, Cell Line, Tumor, medicine, Humans, Thyroid Neoplasms, Promoter Regions, Genetic, Cell Proliferation, Cell growth, Retinoic Acid Receptor alpha, Carcinoma, DNA Methylation, Molecular biology, Demethylating agent, Gene Expression Regulation, Neoplastic, Retinoic acid receptor, medicine.anatomical_structure, chemistry, Organ Specificity, Cell culture, Apoptosis, Azacitidine, Cancer research, Growth inhibition

الوصف: The treatment of both undifferentiated and de-differentiated thyroid tumors, which are unresponsive to radioiodine, represents one of the biggest challenges for thyroidologists. The aim of the present study was to investigate in vitro the methylation status of retinoic acid receptors (RAR)beta2 promoter and the effect of the demethylating agent 5-aza-2'-deoxycytidine (5-Aza-CdR) on 5 human thyroid cancer cell lines. The methylation status of RARbeta2 promoter was analyzed by methylation-specific PCR. The effect of 5-Aza-CdR on cell growth and apoptosis was evaluated by cell counting, enzymelinked immunosorbent assay tests and fluorescence-activated cell sorting analysis, while the effect on the expression of RAR and thyroid-specific genes was measured by qualitative and quantitative RT-PCR. Methylation of RARbeta2 promoter was present only in ARO cells. 5-Aza-CdR determined growth inhibition in all cell lines, probably due to apoptosis in WRO, NPA, and ARO cells, and to inhibition of DNA synthesis in TT cells. Treatment with 5-Aza-CdR induced the expression of RARbeta mRNA in ARO and FRO cells, a slight increase of the expression of Tg, TPO and thyroid trancription factor 1 (TTF-1) mRNA and the new expression of low levels of NIS in TT cells. A significant increase of TTF-1 mRNA in FRO cells was also observed. In this study we demonstrated that RARbeta2 promoter was methylated in ARO cell line. However, the 5-Aza-CdR treatment induced RARbetamRNA expression not only in ARO but also in FRO and TT cell lines, whose RARbeta2 promoter was unmethylated. A significant reduction of cell growth, but not cell re-differentiation, was also observed after 5-Aza-CdR treatment.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::057b5a0b197cb3ec12e8f0d9f9284deeTest
https://doi.org/10.1007/bf03346422Test

المؤلفون: Alexander Arynchyn, Lucia Grasso, Tatiana Mokhort, Furio Pacini, Stefano Mariotti, Eleonora Molinaro, Anatoly F. Tsyb, Ulla Feldt-Rasmussen, Lucio Masserini, Aldo Pinchera, Anders Juul, Tatiana Vorontsova, Rossella Elisei, P Mossa, Laura Agate, Mycola D. Tronko

المصدر: The Journal of Clinical Endocrinology & Metabolism. 93:2729-2736

مصطلحات موضوعية: Male, Radioactive Fallout, medicine.medical_specialty, Adolescent, Republic of Belarus, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Thyroid Gland, Context (language use), Chernobyl Nuclear Accident, Iodide Peroxidase, Biochemistry, Thyroiditis, Russia, Endocrinology, Internal medicine, medicine, Humans, Autoantibodies, Autoimmune disease, business.industry, Biochemistry (medical), Thyroid, Thyroiditis, Autoimmune, Autoantibody, medicine.disease, Anti-thyroid autoantibodies, medicine.anatomical_structure, Female, Thyroid function, Ukraine, business

الوصف: An increase in the prevalence of thyroid autoantibodies (ATAs) was reported 6-8 yr after the Chernobyl accident in radiation-exposed children and adolescents.Our objective was to reassess the effects of childhood radiation exposure on ATAs and thyroid function 13-15 yr after the accident.We measured the antithyroglobulin (TgAbs) and antithyroperoxidase (TPOAbs) antibodies and TSH in 1433 sera collected between 1999 and 2001 from 13- to 17-yr-old adolescents born between January 1982 and October 1986 in paired contaminated and noncontaminated villages of Belarus, Ukraine, and Russia. A total of 1441 sera was collected from age- and sex-matched controls living in Denmark and Sardinia (Italy). Free T(4) and free T(3) were measured when TSH was abnormal.TPOAb prevalence was higher in contaminated than in noncontaminated Belarusian children (6.4 vs. 2.4%; P = 0.02) but lower than previously reported (11%) in a different contaminated Belarus village. No difference in TPOAb prevalence was found in Ukrainian and Russian villages. TgAbs showed no difference between contaminated and noncontaminated Belarus and Ukraine, whereas in Russia they showed a relative increase in the exposed subjects with respect to the unexposed, who showed an unexpectedly lower prevalence of TgAbs. Besides radiation exposure, female gender was the only variable significantly correlated with ATAs in all groups. ATA prevalence in nonexposed villages of Belarus, Ukraine, and Russian Federation did not differ from that found in Sardinia and Denmark. With few exceptions, thyroid function was normal in all study groups.TPOAb prevalence in adolescents exposed to radioactive fallout was still increased in Belarus 13-15 yr after the Chernobyl accident. This increase was less evident than previously reported and was not accompanied by thyroid dysfunction. Our data suggest that radioactive fallout elicited a transient autoimmune reaction, without triggering full-blown thyroid autoimmune disease. Longer observation periods are needed to exclude later effects.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3f5fbade32834fffddd9d9f3fbb54bdTest
https://doi.org/10.1210/jc.2008-0060Test

المؤلفون: Liborio Torregrossa, Gabriele Materazzi, Agnese Biagini, Laura Agate, Clara Ugolini, Paolo Miccoli, Paolo Vitti, Rossella Elisei, Francesca Casella, Raffaele Ciampi, Alessia Tacito, Valeria Bottici, Eleonora Molinaro, Cristina Romei, Fulvio Basolo, David Viola, Antonio Matrone

المصدر: Clinical endocrinology. 82(6)

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Heterozygote, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Thyroid Gland, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b, medicine.disease_cause, Sensitivity and Specificity, Germline, Pathogenesis, Thyroid carcinoma, Exon, Endocrinology, Internal medicine, medicine, Humans, Genetic Testing, Thyroid Neoplasms, Early Detection of Cancer, Germ-Line Mutation, Mutation, business.industry, Proto-Oncogene Proteins c-ret, Medullary thyroid cancer, Middle Aged, medicine.disease, Diabetes and Metabolism, Genetic screening test, Italy, Carcinoma, Medullary, Female, business, Rare disease

الوصف: SummaryObjective Medullary thyroid carcinoma (MTC) is a rare disease that can be inherited or sporadic; its pathogenesis is related to activating mutations in the RET gene. Design This study describes our 20-year experience regarding RET genetic screening in MTC. Patients and methods We performed RET genetic screening in 1556 subjects, 1007 with an apparently sporadic MTC, 95 with a familial form and 454 relatives of RET-positive patients with MTC. Results A germline RET mutation was found in 68 of 1007 (6·7%) patients with sporadic MTC, while 939 patients with MTC were negative for germline RET mutations. We then identified a total of 137 gene carriers (GC). These subjects initiated a clinical evaluation for the diagnosis of MEN 2. A total of 139 MEN 2 families have been followed: 94 FMTC, 33 MEN 2A and 12 MEN 2B. Thirty-three different germline RET mutations were identified. Codon 804 was the most frequently altered codon particularly in FMTC (32/94, 34%), while codon 634 was the most frequently altered codon in MEN 2A (31/33, 94%); MEN 2B cases were exclusively associated with an M918T mutation at exon 16. Conclusions Our 20-year study demonstrated that RET genetic screening is highly specific and sensitive, and it allows the reclassification as hereditary of apparently sporadic cases and the identification of GC who require an adequate follow-up. We confirmed that FMTC is the most prevalent MEN 2 syndrome and that it is strongly correlated with noncysteine RET mutations. According to these findings, a new paradigm of follow-up of hereditary MTC cases might be considered in the next future.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa45040be8f22e6abace03a8087e6f01Test
https://pubmed.ncbi.nlm.nih.gov/25440022Test

المؤلفون: Furio Pacini, Eleonora Molinaro, Aldo Pincheia, Laura Agate, Elvira Kuchinskaya, Tatiana Vorontsova, Elena Shavrova, Larisa Astachova, Luca Chiovato

المصدر: The Lancet. 352:763-766

مصطلحات موضوعية: Male, Radioactive Fallout, endocrine system, medicine.medical_specialty, Adolescent, Republic of Belarus, endocrine system diseases, medicine.medical_treatment, Thyroid Gland, Thyrotropin, Physiology, Thyroglobulin, Sex Factors, Internal medicine, medicine, Humans, Risk factor, Child, Autoantibodies, business.industry, Thyroid, Autoantibody, General Medicine, Anti-thyroid autoantibodies, Thyroxine, Endocrinology, medicine.anatomical_structure, Peroxidases, In utero, Female, Thyroid function, Radioactive Hazard Release, Ukraine, business, Power Plants, Hormone

الوصف: Summary Background The long-term effects of ionising radiation, including radioiodine, on thyroid function are not well known. We compared thyroid immunity and function in two groups of children from Belarus, one of whom was exposed to the radioactive fallout of Chernobyl. Methods We measured serum free thyroxine 4 (free T4), free T3, and thyrotropin hormone (TSH) and the prevalence of thyroid autoantibodies (antithyroglobulin and antithyroperoxidase), in 287 children or adolescents living in Hoiniki (average caesium contamination of 5·4 Ci/km 2 ). We also studied 208 children and adolescents living in Braslav (average contamination 2 ), who were age 12 years or less at the time of the Chernobyl accident. Findings The prevalence of antithyroglobulin or antithyroperoxidase, or both, was significantly higher (p=0·0001) in individuals living in Hoiniki (56 [19·5%] of 287) than in those living in Braslav (eight [3·8%] of 208). In both villages, no sex differences were found in the antibody prevalence before age 13 years. Thereafter, a significantly higher prevalence of thyroid autoantibodies was found in girls from Hoiniki. The increase in the prevalence of circulating antibodies in the contaminated group was already apparent in individuals who, at the time of the accident, were in utero or newborn (15·7%), and was even more pronounced in children of 9 years or more (35·1%). No major alterations of serum FT-4, FT-3, or TSH were found. Interpretation 6–8 years after the Chernobyl accident, a significant increase in thyroid autoimmunity was found in children exposed to radioactive fallout. Pubertal age in girls is a risk factor for increased prevalence of thyroid autoimmunity. The autoimmune phenomena are limited to an increased prevalence of circulating thyroid autoantibodies without evidence of significant thyroid dysfunction. The future development of clinically relevant thyroid autoimmune diseases, especially hypothyroidism, is a possibility.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d10cdb5abcbf158f3fdf2bd8d404858Test
https://doi.org/10.1016/s0140-6736Test(97)11397-6

المؤلفون: Furio Pacini, Paola Collecchi, Rossella Elisei, Eleonora Molinaro, Cristina Romei, Paolo Miccoli, Raffaele Ciampi, Pinuccia Faviana, Aldo Pinchera, Agnese Vivaldi, Fulvio Basolo, Laura Agate, Alessandra Capodanno, Pamela Piampiani

مصطلحات موضوعية: endocrine system, medicine.medical_specialty, Receptors, Retinoic Acid, medicine.drug_class, Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Thyroid Gland, Retinoic acid, Tretinoin, Biology, Biochemistry, chemistry.chemical_compound, Endocrinology, Cell Line, Tumor, Internal medicine, medicine, Humans, RNA, Messenger, Thyroid Neoplasms, Retinoid, Thyroid cancer, Cell Proliferation, Biochemistry (medical), Thyroid, Medullary thyroid cancer, medicine.disease, Immunohistochemistry, Gene Expression Regulation, Neoplastic, Retinoic acid receptor, medicine.anatomical_structure, chemistry, Growth inhibition, medicine.drug

الوصف: Conventional chemotherapy and radiotherapy are ineffective for the treatment of advanced thyroid tumors like poorly differentiated papillary, anaplastic, and medullary thyroid cancer. In the attempt to evaluate the possibility of using retinoic acid (RA) in the treatment of thyroid cancer refractory to conventional therapy, we studied the effect of all-trans-RA treatment on five human thyroid cancer cell lines. We found that WRO and NPA, derived from follicular and poorly differentiated human thyroid carcinoma, respectively, showed a growth inhibition after 25 and 21 d of RA treatment. Both apoptosis and a decrease in DNA synthesis were observed as mechanisms of growth inhibition. In the NPA cell line, a delay of cell-cycle progression has also been observed. On the contrary, we did not observe any recovery of mRNA expression of thyroid-specific genes and in particular of the sodium iodide symporter gene. The lack of recovery of radioiodide uptake after all-trans-RA treatment confirmed the inability to reexpress sodium iodide symporter mRNA. The main difference between the all-trans-RA responding cells (WRO and NPA) and the nonresponding cells [ARO, FRO (derived from human anaplastic thyroid tumors) and TT (derived from human medullary thyroid tumor)] was the basal and all-trans-RA induced RA receptor (RAR)beta mRNA expression. Interestingly, 14 thyroid tumors (10 papillary and four anaplastic) showed a significant lower expression of RARbeta mRNA when compared with normal thyroid tissues. In agreement with this result, only 30% of papillary thyroid carcinomas analyzed were positive for RARbeta protein expression with a degree of expression that was much lower than that found in normal thyroid tissue. In conclusion we found that all-trans-RA treatment can determine a significant in vitro growth inhibition especially in differentiated thyroid tumor-derived cell lines but it seems unable to reinduce the expression of thyroid-specific genes and in particular to reinduce the ability to take up iodine. The growth inhibition is likely due to apoptosis in an early phase and to a decrease of DNA synthesis later. In some cases, a delay of the cell-cycle progression also may be responsible for the growth inhibition. The finding of a basal and RA-induced RARbeta mRNA expression only in cell lines responding to all-trans-RA suggests that the growth inhibition might be mediated by RARbeta.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c318ebd8fe1f84f3bb15cb86b686e942Test
http://hdl.handle.net/11568/181739Test